Kaluz, Stefan
Zhang, Qing
Kuranaga, Yuki
Yang, Hua
Osuka, Satoru
Bhattacharya, Debanjan
Devi, Narra S.
Mun, Jiyoung
Wang, Wei
Zhang, Ruiwen
Goodman, Mark M.
Grossniklaus, Hans E.
Van Meir, Erwin G.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA116804, CA176001, CA180805)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
the V Foundation, the Max Cure Foundation, the Samuel Waxman Cancer Research Foundation, the Alan B. Slifka Foundation
Article History
Received: 3 February 2020
Revised: 10 June 2021
Accepted: 16 June 2021
First Online: 3 July 2021
Declarations (Ethics)
:
: EGVM is an inventor on a patent jointly held by Emory University and Scripps Research Institute that includes the KCN1 compound used in this study. He is also a share-holder of OncoSpherix Inc.